Clinical Trial Update: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 extension study evaluating safety and efficacy of daclizumab high yield process (BIIB019) in participants with relapsing-remitting multiple sclerosis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• daclizumab high yield process (BIIB019) (daclizumab high yield process)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2018-11-09